The Jackson Laboratory’s Post

Opna Bio's Bernice Matusow, MS, presented research yesterday at the American Association of Cancer Research annual meeting on OPN-6602, an EP300/CBP bromodomain inhibitor, which demonstrated potent anti-tumor activity in preclinical models of multiple myeloma. OPN-6602 significantly reduced tumor growth as a single agent (71% tumor growth inhibition) in the OPM-2 human multiple myeloma cell xenograft model as well as increased anti-tumor activity (>100% TGI) in combination studies. Opna plans to initiate a Phase 1 clinical study with OPN-6602 in multiple myeloma patients later this summer. #AACR#multiplemyeloma#Phase1

Watch our webinar to learn how a large cancer center implemented PGDx elioTM tissue complete. Our panel discusses the benefits of rapid biomarker identification, the potential to provide a clearer path to reimbursement and the research opportunities that are possible with PGDx elio tissue complete.

Watch our webinar to learn how a large cancer center implemented PGDx elioTM tissue complete. Our panel discusses the benefits of rapid biomarker identification, the potential to provide a clearer path to reimbursement and the research opportunities that are possible with PGDx elio tissue complete.

Watch our webinar to learn how a large cancer center implemented PGDx elioTM tissue complete. Our panel discusses the benefits of rapid biomarker identification, the potential to provide a clearer path to reimbursement and the research opportunities that are possible with PGDx elio tissue complete.

Watch our webinar to learn how a large cancer center implemented PGDx elioTM tissue complete. Our panel discusses the benefits of rapid biomarker identification, the potential to provide a clearer path to reimbursement and the research opportunities that are possible with PGDx elio tissue complete.

Watch our webinar to learn how a large cancer center implemented PGDx elioTM tissue complete. Our panel discusses the benefits of rapid biomarker identification, the potential to provide a clearer path to reimbursement and the research opportunities that are possible with PGDx elio tissue complete.

An inevitable challenge emerges over time as tumors develop drug resistance, resulting in treatment failure. This resistance is inherent to the tumor cells themselves, as well as tied to factors within the tumor microenvironment (TME). To bolster the research of innovative cancer drugs and to emulate real-world clinical scenarios of tumor resistance, WuXi Biology has developed a comprehensive platform of preclinical drug resistance models leveraging in vivo and in vitro methodologies. Curious to learn more? Watch the video 👇 For more videos, follow along each week or check out our YouTube channel: https://lnkd.in/eVxhJDXg #Biotech #DrugDiscovery #DrugResistance #Cancer #Oncology #PDX #TME https://lnkd.in/eSUzPpH8

Precede Biosciences is pleased to announce new data in #ProstateCancer to be presented at #ESMO24 demonstrating PSMA signal detection from the blood that is highly correlated with quantitative PET imaging for PSMA.   PSMA is a high priority target in prostate cancer, with one medicine FDA-approved and more than 30 PSMA-targeting agents in clinical development.   View our abstract and come speak with us at ESMO to learn how a simple blood-based test for PSMA using our comprehensive epigenomic #LiquidBiopsy platform could emerge as a valuable guide for the next generation of medicines in prostate cancer.   View abstract: https://bit.ly/3TmHIKW #ProstateCancerAwareness #PrecisionMedicine #DrugDevelopment  

Watch our webinar to learn how a large cancer center implemented PGDx elioTM tissue complete. Our panel discusses the benefits of rapid biomarker identification, the potential to provide a clearer path to reimbursement and the research opportunities that are possible with PGDx elio tissue complete.

Watch our webinar to learn how a large cancer center implemented PGDx elioTM tissue complete. Our panel discusses the benefits of rapid biomarker identification, the potential to provide a clearer path to reimbursement and the research opportunities that are possible with PGDx elio tissue complete.